August Innovation

Our News

Innovation Product Pipeline Launches

Our Product Pipeline represents the structured framework Innovation Ventures uses to take a product from an initial concept through the various phases of research, development, testing, and finally to commercial launch and post-market management. Think of it as a GPS that shows where our emerging technologies stand in the commercialization landscape.

This system was developed by our Sr. IP Project & Compliance Manager, Danielle Casey Callaghan, BA, and is supported with up-to-date information by Associate Director, IP & Business Operations, Dan Abel, JD, and Sr. License Compliance Manager, Heather Carrico, MS.

Experience our Product Pipeline

tool in real time for yourself!

Visit Product Pipeline

UCSF NSF I-CORPS

October 2026 Course

Do you have an early-stage healthcare product startup or startup idea?

Apply now for the UCSF NSF I-Corps

October Training Course!

The UCSF National Science Foundation (NSF) I-Corps program will host its training course focused on healthcare products, including therapeutics, diagnostics, medical devices, digital health, and platform technologies, on October 7, 14, and 21 from 5 pm to 8 pm via Zoom. The course is an immersive two-week virtual customer discovery training. You'll learn how to conduct 20 customer interviews to identify your top customer segment and value propositions, validate your commercial market, and accelerate finding your 'product-market fit.'

Apply by September 13

Apply Here

CATALYST ACCELERATOR

Applications Open on August 27

The Catalyst Accelerator is dedicated to advancing UCSF innovations that are novel, impactful, and scalable. The Catalyst Accelerator provides expert advice, service, and mentorship from industry advisors, subject matter experts, and serial innovators to UCSF Principal Investigators (PIs). In addition, Milestone Advancement Plans (MAP) will be developed to advance each of the selected innovations along the translational path to commercialization and patient benefit.

Catalyst Accelerator Awards are issued in a two-step process.

Catalyst Consultation Awardees strengthen the translational and commercial positioning of their projects before delivering a final pitch presentation live and in-person.
Catalyst Final Awardees are selected based on scientific merit, translational feasibility, and commercial potential.

The Catalyst Final Awardee teams use project funding up to $75,000 to advance their project aims and achieve milestones.

Join our August

Information Session

Navigate to the link below to register for upcoming Catalyst Accelerator Awards information sessions on Zoom.

Tuesday August 25, 12-1 pm

Learn More

Get Ready For

The Genotech Symposium 2026!

The UCSF Institute for Human Genetics (IHG) is pleased to partner with the UCSF Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research (Broad Center) to host the Genotech Symposium 2026.

This year's symposium will take place on Wednesday, September 23, from 8:30 AM to 6:30 PM at the William J. Rutter Center, Robertson Auditorium. Building on the success of last year's event, which welcomed more than 500 registrants, we look forward to bringing the genetics and genomics community together once again.

The symposium is designed to foster collaboration and meaningful dialogue between academia and industry in the fields of genetics and genomics. Attendees will have opportunities to exchange ideas, make new connections, and spark collaborations through both the scientific program and informal networking. The program will feature presentations from leading faculty and industry experts, showcasing advances in both basic science and translational research across a broad range of topics in genetics and genomics.

Registration is free, and we encourage you to register by September 7 to help us plan for catering.

RSVP

We hope you'll join us for an engaging day of scientific discovery, collaboration, and networking.

UCSF Tech in the News

Chugai and UCSF Establish Master Collaboration Agreement for Drug Discovery Research

Chugai Pharmaceutical Co. (Chugai) and the University of California, San Francisco (UCSF) have entered into a Master Collaboration Agreement to advance drug discovery research. The multi-year agreement establishes a framework to facilitate research collaborations in areas including the exploration of disease biology, the identification of novel drug targets, and the development of new therapeutic approaches. An initial research project is already underway with a UCSF principal investigator.

Jocasta Signs UCSF Licensing Agreement to Advance α-klotho for Managing Cognitive Impairment

Jocasta Neuroscience, Inc., a biotechnology company developing therapeutics to address neurodegenerative diseases, today announced it has entered into a new licensing agreement with the University of California, San Francisco (UCSF) through its Innovation Ventures office to develop α-klotho-based therapies aimed at enhancing cognitive function.

United Therapeutics Corporation Acquires Thymmune Therapeutics

UCSF Innovation Translates Discovery into Life-Saving Diagnostics

Always more to come!

UCSF | https://innovation.ucsf.edu